Leukemia Clinical Trials in Detroit

Showing 1121-1140 of 1,678 trials

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT03071276

This study will be done in two parts: Phase I (NCT02212561) has been completed and published. The goal of the Phase I portion of this study was to find the highest tolerable dose of selinexor (KPT-330) that can be given to patients with leukemia or myelodysplastic syndrome (MDS), when it is combined with fludarabine and cytarabine. The Phase II portion of the protocol is reflected in this registration. The goal of the Phase II portion of this protocol is to give the highest dose of selinexor (KPT-330) in combination with fludarabine/cytarabine that was found in Phase I to be safe for children with acute myeloid leukemia (AML). The investigators will examine the effect of this combination treatment.

Acute Myeloid Leukemia (AML)

St. Jude Children's Research Hospital37 participantsStarted Jan 2016

Phoenix, Arizona, United States • Palo Alto, California, United States • Chicago, Illinois, United States +4 more locations

COMPLETEDPhase 2< 1 mile

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

NCT01154816

This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia. Alisertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

HepatoblastomaPreviously Treated Childhood RhabdomyosarcomaRecurrent Childhood Acute Lymphoblastic Leukemia+8 more

Children's Oncology Group118 participantsStarted Feb 2011

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Little Rock, Arkansas, United States +102 more locations

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Leukemia Trials in Other Cities

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC

A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Analyses of Human Samples Collected in Clinical Trials

NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases

Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer

Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy

Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Study Comparing OsseoSpeed™ Implants of Two Different Lengths in the Upper and Lower Posterior Jaw

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Other Conditions in Detroit